Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Argo will receive an upfront payment of $160 million and is eligible for potential milestone and option payments of up to $5.2 billion, plus tiered royalties.…
Novartis is once again turning to Argo Biopharma, this time handing over $60 million upfront and up to $5.2 billion in biobucks for a multi-asset…
Novartis pens $5.2bn cardiovascular partnership with Argo, paying $160 million upfront for an R&D alliance covering multiple cardiovascular siRNA drugs.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Novartis expanded its collaboration with Argo Biopharma for multiple cardiovascular siRNA assets - the third transaction between the parties. Argo receives $160M upfront, up to $5.2B in milestone and option payments, and tiered royalties. Includes an option on ex-China rights to two discovery-stage molecules for severe hypertriglyceridemia / mixed dyslipidemia, a right of first negotiation on BW-00112 (ANGPTL3, Phase 2), and a license to an additional IND-enabling hepatic siRNA. Novartis also signaled a non-binding intention to join Argo's next equity financing round.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Argo Biopharmaceutical Co., Ltd. (this deal) | 2025 | $5.3B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2025 deals · Novartis AG deals · Cardiovascular deals